Hester Biosciences DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.91×	0.83×	0.81×	0.77×	0.78×
	2.31×	1.02×	0.80×	0.75×	1.19×
	19.9%	20.4%	14.2%	12.0%	11.2%
	0.50×	0.50×	0.47×	0.46×	0.43×
	1.84×	1.84×	2.00×	2.19×	2.32×
	38.7%	15.9%	8.7%	7.0%	10.5%
	16.5%	16.5%	9.1%	6.6%	9.9%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

HESTERBIO₹2,054.00

Hester Biosciences Limited

· Pharma & Health

₹ CrorePeersWINDLAS SYNCOMF NGLFINE INDOCO SAIPARENT JAGSNPHARM PANACEABIOMcap ₹1,747 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.78	0.77	0.81	0.83	0.91
Interest Burden (Pretax/EBIT) ×	1.19	0.75	0.80	1.02	2.31
EBIT Margin %	11.24	11.98	14.22	20.38	19.92
Asset Turnover ×	0.43	0.46	0.47	0.50	0.50
Financial Leverage (Assets/Equity) ×	2.32	2.19	2.00	1.84	1.84
ROE (5-step product, year-end total equity) %	10.52	6.99	8.71	15.93	38.74
ROE (owners' profit / average owners' equity) %	9.87	6.61	9.07	16.50	16.50

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.